Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease

Nature Clinical Practice Nephrology volume 3, pages 646–647 (2007)Cite this article

boxed-text Lin-Tan DT et al. (2007) Long-term outcome of repeated lead chelation therapy in progressive non-diabetic chronic kidney diseases. Nephrol Dial Transplant [doi:10.1093/ndt/gfm342]

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Muntner P et al. (2003) Blood lead and chronic kidney disease in the general United States population: results from NHANES III. Kidney Int 63: 1044–1050

    Article  Google Scholar 

  2. Batuman V (1993) Lead nephropathy, gout, and hypertension. Am J Med Sci 305: 241–247

    Article  CAS  Google Scholar 

  3. Muntner P et al. (2005) Continued decline in blood lead levels among adults in the United States: the National Health and Nutrition Examination Surveys. Arch Intern Med 165: 2155–2161

    Article  CAS  Google Scholar 

  4. Lin JL et al. (1999) Chelation therapy for patients with elevated body lead burden and progressive renal insufficiency: a randomized, controlled trial. Ann Intern Med 130: 7–13

    Article  CAS  Google Scholar 

  5. Lin JL et al. (2003) Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 348: 277–286

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Nephrology Section-SL45, Tulane University Medical Center, 1430 Tulane Avenue, New Orleans, LA 70112-2632, USA vbatuma@tulane.edu

Authors and Affiliations

  1. V Batuman is a Professor of Medicine at Tulane University School of Medicine and Chief of the Medicine Service at the Veterans Affairs Medical Center in New Orleans, LA, USA.,

    Vecihi Batuman

Authors
  1. Vecihi Batuman
    View author publications

    Search author on:PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Batuman, V. Lead chelation therapy retards the decline of renal function in patients with chronic kidney disease. Nat Rev Nephrol 3, 646–647 (2007). https://doi.org/10.1038/ncpneph0617

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ncpneph0617

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing